Compare PMCB & QCLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | QCLS |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.2M |
| IPO Year | 2001 | 2013 |
| Metric | PMCB | QCLS |
|---|---|---|
| Price | $0.44 | $0.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 302.6K | ★ 6.0M |
| Earning Date | 03-17-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,929,527.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.71 |
| 52 Week Low | $0.33 | $0.42 |
| 52 Week High | $1.51 | $8.17 |
| Indicator | PMCB | QCLS |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 31.72 |
| Support Level | $0.33 | $0.42 |
| Resistance Level | $0.77 | $4.09 |
| Average True Range (ATR) | 0.05 | 0.26 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 63.10 | 28.63 |
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.